1. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Issue 7 (July 2017) Authors: Cameron, David; Morden, James P; Canney, Peter; Velikova, Galina; Coleman, Robert; Bartlett, John; Agrawal, Rajiv; Banerji, Jane; Bertelli, Gianfilippo; Bloomfield, David; Brunt, A Murray; Earl, Helena; Ellis, Paul; Gaunt, Claire; Gillman, Alexa; Hearfield, Nicholas; Laing, Robert; Murray, Nichol... Journal: Lancet oncology Issue: Volume 18:Issue 7(2017:Jul.) Page Start: 929 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗